Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Symptomatic supportive treatment | No Intervention | Symptomatic supportive treatment | |
| Abidol hydrochloride was added on the basis of group I. | Experimental | Abidol hydrochloride 0.2g once,3 times a day,2 weeks |
|
| Oseltamivir was added on the basis of group I. | Experimental | Oseltamivir 75mg once,twice a day,2 weeks |
|
| Lopinavir/ritonavir was added on the basis of group I. | Experimental | Lopinavir/ritonavir 500mg once,twice a day,2 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Abidol hydrochloride | Drug | Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of disease remission | A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2> 93% or PaO2/FiO2>300mmHg (1mmHg=0.133Kpa); | two weeks |
| Time for lung recovery | Compare the average time of lung imaging recovery after 2 weeks of treatment in each group. | two weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of no fever | two weeks | |
| Rate of respiratory symptom remission | two weeks | |
| Rate of lung imaging recovery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Qing Ning, Professor | Contact | +8613971521450 | qning@vip.sina.com | |
| Meifang Han, Professor | Contact | +8613986093605 | mfhan@foxmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department and Institute of Infectious Disease | Recruiting | Wuhan | Hubei | 430030 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D053139 | Oseltamivir |
| D061466 | Lopinavir |
| ID | Term |
|---|---|
| D000081 | Acetamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D053138 | Cyclohexenes |
| D003510 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Oseltamivir | Drug | Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I. |
|
| Lopinavir/ritonavir | Drug | Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I. |
|
| two weeks |
| Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery | two weeks |
| Rate of undetectable viral RNA | two weeks |
| Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |